Dillon's Trial. Dillon Papier takes his nightly bath. Dillon, 11, has Niemann–Pick type C, a degenerative, rare and ultimately fatal disease. In spite of this, and despite the physical and developmental setbacks that came with the disease, his parents strive to provide him with a normal childhood that revolves around school, playdates and family outings when Dillon is not in the hospital. He is currently enrolled in a clinical drug trial at the National Institutes of Health, the second such trial this year. The first, involving a special reservoir implanted in his brain, had to be ended when Dillon and other patients developed infections. The new trial involves a lumbar injection of the drug Cyclodextrin.
Dillon's Trial. A neurosurgeon maps Dillon Papier's brain in advance of the procedure to place an Ommaya reservoir into his brain, allowing for direct injection of the clinical trial drug Cyclodextrin. This particular trial had to be ended after Dillon and other patients developed dangerous infections.